Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TEBE-AM: tebentafusp alone or with pembrolizumab versus investigator's choice in previously treated advanced melanoma
2022-502732-39-00Phase 3Authorised
- Sponsor
- Immunocore
- Start
- Sep 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 12
01
Overview
Phase 3, randomised, open-label trial of tebentafusp and pembrolizumab in melanoma (3 arms), sponsored by Immunocore. Primary endpoints: Overall survival and Substudy cytokine release syndrome and healthcare utilization endpoints. Planned start Sep 2023; status: authorised.
02
Drugs
tebentafusppembrolizumab
03
Conditions
melanoma
Beyond the preview
Go deeper on 2022-502732-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502732-39-00.